Bambusa Therapeutics raised $90 million in a Series A financing led by RA Capital Management to advance bispecific antibodies for immunology and inflammation diseases.
Amount Raised
$90 Million
Round Type
Series A
BostonBiotechnologyHealth CareTherapeuticsInvestors
Description
Bambusa Therapeutics, a biotechnology company, announced the completion of its oversubscribed Series A financing of approximately $90 million. The funding will support the advancement of Bambusa's lead programs through Phase I trials and drive further pipeline development.
Quick answer
Bambusa Therapeutics raised $90 Million in a Series A round, dated February 14, 2025. Investors: Adar1 Capital Management, Invus, Redmile Group, Janus Henderson Investors and RA Capital Management. Bambusa Therapeutics is based in Boston, Massachusetts, United States.
- How much did Bambusa Therapeutics raise?
- Bambusa Therapeutics raised $90 Million in a Series A round on February 14, 2025.
- Who invested in Bambusa Therapeutics?
- Adar1 Capital Management, Invus, Redmile Group, Janus Henderson Investors and RA Capital Management are named as investors in this round.
- What does Bambusa Therapeutics do?
- Bambusa Therapeutics believes the I&I field is long overdue for innovative approaches and transformative therapeutics.
- Where is Bambusa Therapeutics based and how big is it?
- Bambusa Therapeutics is based in Boston, Massachusetts, United States. Fundz records about 12 employees.
- Who are the decision-makers at Bambusa Therapeutics?
- Fundz holds 2 contacts at Bambusa Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Bambusa Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- NewcelX raised $2M (Seed) on March 28, 2025.
- Epicrispr Biotechnologies raised $68M (Series B) on March 27, 2025.
- Tribune Therapeutics raised $40M (Seed) on March 26, 2025.
- Surrozen raised $76M on March 26, 2025.
- Hillstar Bio raised $67M (Series A) on March 25, 2025.
- Tempero Bio raised $70M (Series B) on March 24, 2025.
Who to call at Bambusa Therapeutics, and when
A new round usually means Bambusa Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Bambusa Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Bambusa Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Bambusa Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Bambusa Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansBambusa Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.